## Pascual Sanz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3544342/publications.pdf

Version: 2024-02-01

136	5,493	70961 41 h-index	64
papers	citations		g-index
141	141	141	6773 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Regulatory Interactions between the Reg1-Glc7 Protein Phosphatase and the Snf1 Protein Kinase. Molecular and Cellular Biology, 2000, 20, 1321-1328.	1.1	222
2	A 13C Nuclear Magnetic Resonance Investigation of the Metabolism of Leucine to Isoamyl Alcohol in Saccharomyces cerevisiae. Journal of Biological Chemistry, 1997, 272, 26871-26878.	1.6	177
3	Severe Persistent Hyperinsulinemic Hypoglycemia due to a De Novo Glucokinase Mutation. Diabetes, 2004, 53, 2164-2168.	0.3	174
4	Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Human Molecular Genetics, 2010, 19, 2867-2876.	1.4	170
5	Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Human Molecular Genetics, 2012, 21, 1521-1533.	1.4	131
6	Regulation of glycogen synthesis by the laforin–malin complex is modulated by the AMP-activated protein kinase pathway. Human Molecular Genetics, 2008, 17, 667-678.	1.4	128
7	Frataxin interacts functionally with mitochondrial electron transport chain proteins. Human Molecular Genetics, 2005, 14, 2091-2098.	1.4	124
8	Carbon Source-Dependent Phosphorylation of Hexokinase PII and Its Role in the Glucose-Signaling Response in Yeast. Molecular and Cellular Biology, 1998, 18, 2940-2948.	1.1	112
9	Engineering baker's yeast: room for improvement. Trends in Biotechnology, 1999, 17, 237-244.	4.9	106
10	Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Human Molecular Genetics, 2003, 12, 3161-3171.	1.4	102
11	<scp>AMPK</scp> α1â€ <scp>LDH</scp> pathway regulates muscle stem cell selfâ€renewal by controlling metabolic homeostasis. EMBO Journal, 2017, 36, 1946-1962.	3.5	95
12	A PTG Variant Contributes to a Milder Phenotype in Lafora Disease. PLoS ONE, 2011, 6, e21294.	1.1	93
13	Hexokinase PII has a double cytosolic-nuclear localisation inSaccharomyces cerevisiae. FEBS Letters, 1998, 425, 475-478.	1.3	90
14	Reactive Glia Inflammatory Signaling Pathways and Epilepsy. International Journal of Molecular Sciences, 2020, 21, 4096.	1.8	90
15	Convergence of the Target of Rapamycin and the Snf1 Protein Kinase Pathways in the Regulation of the Subcellular Localization of Msn2, a Transcriptional Activator of STRE (Stress Response) Tj ETQq1 1 0.784314 rgBT	<b>/O</b> verlock	<b>80</b> Tf 50 17
16	Large Islets, Beta-Cell Proliferation, and a Glucokinase Mutation. New England Journal of Medicine, 2010, 362, 1348-1350.	13.9	81
17	AMP-Activated Protein Kinase: Structure and Regulation. Current Protein and Peptide Science, 2008, 9, 478-492.	0.7	80
18	In vivo and in vitro analysis of ptl1, a yeast ts mutant with a membrane-associated defect in protein translocation EMBO Journal, 1988, 7, 4347-4353.	3.5	78

#	Article	IF	CITATIONS
19	A769662, a novel activator of AMPâ€activated protein kinase, inhibits nonâ€proteolytic components of the 26S proteasome by an AMPKâ€independent mechanism. FEBS Letters, 2008, 582, 2650-2654.	1.3	76
20	Snf1 protein kinase: a key player in the response to cellular stress in yeast. Biochemical Society Transactions, 2003, 31, 178-181.	1.6	75
21	Reg1p targets protein phosphatase 1 to dephosphorylate hexokinase II in Saccharomyces cerevisiae: characterizing the effects of a phosphatase subunit on the yeast proteome. EMBO Journal, 1999, 18, 4157-4168.	3.5	74
22	Molecular Characterization of Ypi1, a Novel Saccharomyces cerevisiae Type 1 Protein Phosphatase Inhibitor. Journal of Biological Chemistry, 2003, 278, 47744-47752.	1.6	69
23	Increased Endoplasmic Reticulum Stress and Decreased Proteasomal Function in Lafora Disease Models Lacking the Phosphatase Laforin. PLoS ONE, 2009, 4, e5907.	1.1	69
24	Role of AMP-activated protein kinase in autophagy and proteasome function. Biochemical and Biophysical Research Communications, 2008, 369, 964-968.	1.0	67
25	The PP1-R6 protein phosphatase holoenzyme is involved in the glucose-induced dephosphorylation and inactivation of AMP-activated protein kinase, a key regulator of insulin secretion, in MIN6 $\hat{I}^2$ cells. FASEB Journal, 2010, 24, 5080-5091.	0.2	66
26	Active Snf1 protein kinase inhibits expression of the Saccharomyces cerevisiae HXT1 glucose transporter gene. Biochemical Journal, 2002, 368, 657-663.	1.7	63
27	Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii. FEBS Journal, 2013, 280, 525-537.	2.2	63
28	An Attachment-Independent Biochemical Timer of the Spindle Assembly Checkpoint. Molecular Cell, 2017, 68, 715-730.e5.	4.5	62
29	A Complex of Catalytically Inactive Protein Phosphatase-1 Sandwiched between Sds22 and Inhibitor-3. Biochemistry, 2007, 46, 8909-8919.	1.2	59
30	Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease. Molecular Neurobiology, 2016, 53, 1296-1309.	1.9	59
31	Structural Mechanism of Laforin Function in Glycogen Dephosphorylation and Lafora Disease. Molecular Cell, 2015, 57, 261-272.	4.5	54
32	AMP-activated Protein Kinase Phosphorylates R5/PTG, the Glycogen Targeting Subunit of the R5/PTG-Protein Phosphatase 1 Holoenzyme, and Accelerates Its Down-regulation by the Laforin-Malin Complex. Journal of Biological Chemistry, 2009, 284, 8247-8255.	1.6	53
33	The Laforin–Malin Complex, Involved in Lafora Disease, Promotes the Incorporation of K63-linked Ubiquitin Chains into AMP-activated Protein Kinase β Subunits. Molecular Biology of the Cell, 2010, 21, 2578-2588.	0.9	53
34	Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models. Molecular Neurobiology, 2017, 54, 3119-3130.	1.9	53
35	YPI1 and SDS22 Proteins Regulate the Nuclear Localization and Function of Yeast Type 1 Phosphatase Glc7. Journal of Biological Chemistry, 2007, 282, 3282-3292.	1.6	50
36	Astrocytes: new players in progressive myoclonus epilepsy of Lafora type. Human Molecular Genetics, 2018, 27, 1290-1300.	1.4	50

#	Article	IF	Citations
37	In vivo and in vitro analysis of ptl1, a yeast ts mutant with a membrane-associated defect in protein translocation. EMBO Journal, 1988, 7, 4347-53.	3.5	49
38	Clinical and Pathological Findings in Fatal Plant Oxalosis. American Journal of Forensic Medicine and Pathology, 1992, 13, 342-345.	0.4	46
39	DOGR1 andDOGR2: Two genes fromSaccharomyces cerevisiae that confer 2-deoxyglucose resistance when overexpressed. Yeast, 1995, 11, 1233-1240.	0.8	46
40	Purification and characterization of a new $\hat{l}_{\pm}$ -amylase of intermediate thermal stability from the yeast Lipomyces kononenkoae. Biochemistry and Cell Biology, 1995, 73, 41-49.	0.9	46
41	Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease. Experimental and Molecular Medicine, 2019, 51, 1-16.	3.2	46
42	Glucose and Type 2A Protein Phosphatase Regulate the Interaction Between Catalytic and Regulatory Subunits of AMP-activated Protein Kinase. Journal of Molecular Biology, 2003, 333, 201-209.	2.0	44
43	Expression of the HXT1 Low Affinity Glucose Transporter Requires the Coordinated Activities of the HOG and Glucose Signalling Pathways. Journal of Biological Chemistry, 2004, 279, 22010-22019.	1.6	44
44	Reactive Glia-Derived Neuroinflammation: a Novel Hallmark in Lafora Progressive Myoclonus Epilepsy That Progresses with Age. Molecular Neurobiology, 2020, 57, 1607-1621.	1.9	43
45	Signal recognition particle (SRP) stabilizes the translocation-competent conformation of pre-secretory proteins EMBO Journal, 1988, 7, 3553-3557.	3.5	42
46	Secretion in yeast: preprotein binding to a membrane receptor and ATP-dependent translocation are sequential and separable events in vitro Journal of Cell Biology, 1989, 108, 2101-2106.	2.3	42
47	Hexokinase PII: structural analysis and glucose signalling in the yeastSaccharomyces cerevisiae. Yeast, 2001, 18, 923-930.	0.8	40
48	Sumoylation of AMPK $\hat{I}^2$ 2 subunit enhances AMP-activated protein kinase activity. Molecular Biology of the Cell, 2013, 24, 1801-1811.	0.9	40
49	<scp>AMPK</scp> beta subunits: more than just a scaffold in the formation of <scp>AMPK</scp> complex. FEBS Journal, 2013, 280, 3723-3733.	2.2	40
50	Purification and characterization of a neutral endoxylanase from Aspergillus nidulans. FEMS Microbiology Letters, 1993, 113, 223-228.	0.7	39
51	Construction of baker's yeast strains that secrete Aspergillus oryzae alpha-amylase and their use in bread making. Journal of Cereal Science, 1995, 21, 185-193.	1.8	39
52	Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin–malin complex. International Journal of Biochemistry and Cell Biology, 2013, 45, 1479-1488.	1.2	39
53	Increased Oxidative Stress and Impaired Antioxidant Response in Lafora Disease. Molecular Neurobiology, 2015, 51, 932-946.	1.9	39
54	Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration. Antioxidants, 2020, 9, 313.	2.2	39

#	Article	IF	Citations
55	Stable High-Copy-Number Integration of Aspergillus oryzae α-AMYLASE cDNA in an Industrial Baker's Yeast Strain. Biotechnology Progress, 1999, 15, 459-466.	1.3	38
56	Lafora Disease: A Ubiquitination-Related Pathology. Cells, 2018, 7, 87.	1.8	38
57	Glucose repression may involve processes with different sugar kinase requirements. Journal of Bacteriology, 1996, 178, 4721-4723.	1.0	36
58	4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease. NeuroReport, 2017, 28, 268-271.	0.6	35
59	Expression of LIP1 and LIP2 Genes from Geotrichum Species in Baker's Yeast Strains and Their Application to the Bread-Making Process. Journal of Agricultural and Food Chemistry, 1999, 47, 803-808.	2.4	34
60	Saccharomyces cerevisiae 14-3-3 proteins Bmh1 and Bmh2 participate in the process of catabolite inactivation of maltose permease. FEBS Letters, 2003, 544, 160-164.	1.3	31
61	Opposite Clinical Phenotypes of Glucokinase Disease: Description of a Novel Activating Mutation and Contiguous Inactivating Mutations in Human Glucokinase (GCK) Gene. Molecular Endocrinology, 2009, 23, 1983-1989.	3.7	30
62	Impaired autophagy in Lafora disease. Autophagy, 2010, 6, 991-993.	4.3	30
63	Molecular characterization of a gene that confers 2-deoxyglucose resistance in yeast. Yeast, 1994, 10, 1195-1202.	0.8	29
64	Construction of industrial baker's yeast strains able to assimilate maltose under catabolite repression conditions. Applied Microbiology and Biotechnology, 1994, 42, 581-586.	1.7	29
65	Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochemical Journal, 2011, 439, 265-275.	1.7	29
66	Plasmodium falciparum Inhibitor-3 Homolog Increases Protein Phosphatase Type 1 Activity and Is Essential for Parasitic Survival. Journal of Biological Chemistry, 2012, 287, 1306-1321.	1.6	29
67	The expression of a specific 2-deoxyglucose-6P phosphatase prevents catabolite repression mediated by 2-deoxyglucose in yeast. Current Genetics, 1995, 28, 101-107.	0.8	28
68	Human pancreatic glucokinase (GlkB) complements the glucose signalling defect of Saccharomyces cerevisiae hxk2 mutants. Yeast, 2001, 18, 1309-1316.	0.8	28
69	Histone carbonylation occurs in proliferating cells. Free Radical Biology and Medicine, 2012, 52, 1453-1464.	1.3	28
70	Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy. Free Radical Biology and Medicine, 2015, 88, 30-41.	1.3	28
71	Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1074-1083.	1.8	27
72	Combined Expression of Aspergillus nidulans Endoxylanase X24 and Aspergillus oryzae (alpha)-Amylase in Industrial Baker's Yeasts and Their Use in Bread Making. Applied and Environmental Microbiology, 1996, 62, 3712-3715.	1.4	27

#	Article	IF	Citations
73	TRIP6 transcriptional co-activator is a novel substrate of AMP-activated protein kinase. Cellular Signalling, 2006, 18, 1702-1712.	1.7	26
74	Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin–laforin E3-ubiquitin ligase complex. International Journal of Biochemistry and Cell Biology, 2015, 69, 204-214.	1.2	26
75	Cloning and characterization of the SEC18 gene from Candida albicans. Yeast, 1993, 9, 875-887.	0.8	25
76	A Conserved Sequence Immediately N-terminal to the Bateman Domains in AMP-activated Protein Kinase $\hat{I}^3$ Subunits Is Required for the Interaction with the $\hat{I}^2$ Subunits. Journal of Biological Chemistry, 2007, 282, 16117-16125.	1.6	25
77	Laforin, a Dual Specificity Phosphatase Involved in Lafora Disease, Is Present Mainly as Monomeric Form with Full Phosphatase Activity. PLoS ONE, 2011, 6, e24040.	1.1	25
78	Deciphering the role of malin in the lafora progressive myoclonus epilepsy. IUBMB Life, 2012, 64, 801-808.	1.5	25
79	Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase. International Journal of Biochemistry and Cell Biology, 2009, 41, 2431-2439.	1.2	24
80	The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2. BMC Biochemistry, 2015, 16, 24.	4.4	24
81	Sip5 Interacts With Both the Reg1/Glc7 Protein Phosphatase and the Snf1 Protein Kinase of Saccharomyces cerevisiae. Genetics, 2000, 154, 99-107.	1.2	24
82	Diagnostic Difficulties in Glucokinase Hyperinsulinism. Hormone and Metabolic Research, 2009, 41, 320-326.	0.7	23
83	Lafora disease E3-ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level. BMC Evolutionary Biology, 2011, 11, 225.	3.2	23
84	AMPK in Yeast: The SNF1 (Sucrose Non-fermenting 1) Protein Kinase Complex. Exs, 2016, 107, 353-374.	1.4	23
85	TOR kinase pathway and 14-3-3 proteins regulate glucose-induced expression of HXT1, a yeast low-affinity glucose transporter. Yeast, 2005, 22, 471-479.	0.8	22
86	Degradation of altered mitochondria by autophagy is impaired in Lafora disease. FEBS Journal, 2018, 285, 2071-2090.	2.2	22
87	Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease. Autophagy, 2012, 8, 701-703.	4.3	21
88	Signal recognition particle (SRP) stabilizes the translocation-competent conformation of pre-secretory proteins. EMBO Journal, 1988, 7, 3553-7.	3.5	21
89	Expression ofAspergillus oryzaeα-amylase gene inSaccharomyces cerevisiae. FEMS Microbiology Letters, 1993, 112, 119-124.	0.7	20
90	Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism. Journal of Molecular Medicine, 2011, 89, 915-925.	1.7	20

#	Article	IF	CITATIONS
91	Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118613.	1.9	20
92	Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model. Molecular Neurobiology, 2021, 58, 2508-2522.	1.9	19
93	Structure-function analysis of the $\hat{l}\pm 5$ and the $\hat{l}\pm 13$ helices of human glucokinase: Description of two novel activating mutations. Protein Science, 2005, 14, 2080-2086.	3.1	18
94	Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities. Expert Reviews in Molecular Medicine, 2020, 22, e4.	1.6	18
95	Construction of Baker's Yeast Strains that Secrete Different Xylanolytic Enzymes and their use in Bread Making. Journal of Cereal Science, 1997, 26, 195-199.	1.8	17
96	Expression and secretion of Bacillus polymyxane opullulanase in Saccharomyces cerevisiae. FEMS Microbiology Letters, 1999, 170, 41-49.	0.7	17
97	The Saccharomyces cerevisiae 14-3-3 protein Bmh2 is required for regulation of the phosphorylation status of Fin1, a novel intermediate filament protein. Biochemical Journal, 2002, 365, 51-56.	1.7	17
98	The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic. Epilepsy and Behavior, 2020, 103, 106839.	0.9	17
99	The PP1â€R6 protein phosphatase holoenzyme is involved in the glucoseâ€induced dephosphorylation and inactivation of AMPâ€activated protein kinase, a key regulator of insulin secretion, in MIN6 β cells. FASEB Journal, 2010, 24, 5080-5091.	0.2	17
100	Characterization of novel neopullulanase fromBacillus polymyxa. Applied Biochemistry and Biotechnology, 1997, 68, 113-120.	1.4	16
101	Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice. Human Molecular Genetics, 2011, 20, 2571-2584.	1.4	16
102	Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease. International Journal of Molecular Sciences, 2021, 22, 5351.	1.8	16
103	Secretory pattern of a major integral mannoprotein of the yeast cell wall. Biochimica Et Biophysica Acta - General Subjects, 1987, 924, 193-203.	1.1	15
104	Dimerization of the Glucan Phosphatase Laforin Requires the Participation of Cysteine 329. PLoS ONE, 2013, 8, e69523.	1.1	15
105	Studying Closed Hydrodynamic Models of "In Vivo―DNA Perfusion in Pig Liver for Gene Therapy Translation to Humans. PLoS ONE, 2016, 11, e0163898.	1.1	15
106	In vivo glutamate clearance defects in a mouse model of Lafora disease. Experimental Neurology, 2019, 320, 112959.	2.0	15
107	Disseminated Intravascular Coagulation and Mesenteric Venous Thrombosis in Fatal Amanita Poisoning. Human Toxicology, 1988, 7, 199-201.	0.9	14
108	Lafora disease fibroblasts exemplify the molecular interdependence between thioredoxin 1 and the proteasome in mammalian cells. Free Radical Biology and Medicine, 2013, 65, 347-359.	1.3	14

#	Article	IF	CITATIONS
109	Synergistic activation of AMPK prevents from polyglutamine-induced toxicity in Caenorhabditis elegans. Pharmacological Research, 2020, 161, 105105.	3.1	14
110	Cannabidiol-Enriched Extract Reduced the Cognitive Impairment but Not the Epileptic Seizures in a Lafora Disease Animal Model. Cannabis and Cannabinoid Research, 2020, 5, 150-163.	1.5	13
111	Biochemical characterization of novel glucokinase mutations isolated from Spanish maturity-onset diabetes of the young (MODY2) patients. Journal of Human Genetics, 2008, 53, 460-466.	1.1	12
112	Yeast as a model system to study glucose-mediated signalling and response. Frontiers in Bioscience - Landmark, 2007, 12, 2358.	3.0	12
113	Fatal mushroom poisoning in Barcelona, 1986?1988. Mycopathologia, 1989, 108, 207-209.	1.3	11
114	Gene expression analysis method integration and co-expression module detection applied to rare glucide metabolism disorders using ExpHunterSuite. Scientific Reports, 2021, 11, 15062.	1.6	11
115	The Bacillus subtilis lipoprotein LpIA causes cell lysis when expressed in Escherichia coli. Microbiology (United Kingdom), 1994, 140, 1839-1845.	0.7	10
116	Glucoseâ€dependent regulation of AMPâ€activated protein kinase in MIN6 beta cells is not affected by the protein kinase A pathway. FEBS Letters, 2012, 586, 4241-4247.	1.3	10
117	A novel EPM2A mutation yields a slow progression form of Lafora disease. Epilepsy Research, 2018, 145, 169-177.	0.8	10
118	TRIM32 and Malin in Neurological and Neuromuscular Rare Diseases. Cells, 2021, 10, 820.	1.8	10
119	Role of glycosylation in the incorporation of intrinsic mannoproteins into cell walls of Saccharomyces cerevisiae. FEMS Microbiology Letters, 1989, 57, 265-268.	0.7	9
120	Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: Implications in <scp>Lafora</scp> disease. Glia, 2021, 69, 1170-1183.	2.5	9
121	Human pancreatic $\hat{l}^2$ -cell glucokinase: subcellular localization and glucose repression signalling function in the yeast cell. Biochemical Journal, 2008, 415, 233-239.	1.7	8
122	Structure-Function Analysis of PPP1R3D, a Protein Phosphatase 1 Targeting Subunit, Reveals a Binding Motif for 14-3-3 Proteins which Regulates its Glycogenic Properties. PLoS ONE, 2015, 10, e0131476.	1,1	8
123	The interaction between AMPK $\hat{I}^2$ 2 and the PP1-targeting subunit R6 is dynamically regulated by intracellular glycogen content. Biochemical Journal, 2016, 473, 937-947.	1.7	8
124	An empirical pipeline for personalized diagnosis of Lafora disease mutations. IScience, 2021, 24, 103276.	1.9	7
125	Nucleotide sequence of a putative peroxisomal protein from the yeastLipomyces kononenkoae. FEMS Microbiology Letters, 1994, 122, 153-157.	0.7	6
126	New mutations of that partially relieve both glucose and galactose repression activate the protein kinase Snf1. FEMS Yeast Research, 2003, 3, 77-84.	1.1	6

#	Article	IF	CITATIONS
127	Title is missing!. Biotechnology Letters, 1999, 21, 225-229.	1.1	5
128	Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model. Molecular Neurobiology, 2022, 59, 6018-6032.	1.9	5
129	Disruption and functional analysis of six ORFs on chromosome IV: YDL053c, YDL072c, YDL073w, YDL076c, YDL077c and YDL080c. Yeast, 2000, 16, 1437-1443.	0.8	4
130	Increased oxidative stress and impaired antioxidant response in Lafora disease. Free Radical Biology and Medicine, 2014, 75, S47.	1.3	4
131	Assessing the Biological Activity of the Glucan Phosphatase Laforin. Methods in Molecular Biology, 2016, 1447, 107-119.	0.4	3
132	AMPK Protein Interaction Analyses by Yeast Two-Hybrid. Methods in Molecular Biology, 2018, 1732, 143-157.	0.4	3
133	Neuroprotective Effect of IND1316, an Indole-Based AMPK Activator, in Animal Models of Huntington Disease. ACS Chemical Neuroscience, 2022, 13, 275-287.	1.7	3
134	Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Human Molecular Genetics, 2012, 21, 4366-4366.	1.4	1
135	Receptor-mediated binding of secretory protein precursors to endoplasmic reticulum membranes in yeast. Biochemical Society Transactions, 1990, 18, 143-146.	1.6	0
136	The Bacillus subtilis lplA gene is a component of a cluster coding for a putative ABC transporter Journal of General and Applied Microbiology, 1995, 41, 523-528.	0.4	0